Treatment of vascular risk factors is associated with slower decline in Alzheimer disease
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is growing evidence that vascular risk factors (VRF) contribute to cognitive decline. Whether their treatment can slow down the progression of Alzheimer disease (AD) remains unsettled. The aim of this observational study was to evaluate whether the treatment of VRF is associated with a slower cognitive decline in patients who have AD without cerebrovascular disease (CVD). METHODS: We recruited 301 consecutive patients who had AD without CVD (mean age 71.7 years; 69.4% women; first Mini-Mental State Examination [MMSE] mean score 21.6; mean follow-up 2.3 years), who had attended a memory clinic between 1997 and 2003. VRF sought were high blood pressure, dyslipidemia, diabetes mellitus, tobacco smoking, and atherosclerotic disease. Only 21 patients (7.0%) had no VRF. Others were classified as having no VRF treated (n = 72; 25.7%), some VRF treated (n = 119; 42.5%), or all VRF treated (n = 89; 31.8%). We compared MMSE progression over time among these 3 groups using a mixed random effects regression model. RESULTS: Baseline MMSE scores were similar in the 3 groups. With adjustment for confounding factors, MMSE progression over time differed significantly between groups (p = 0.002). Patients with all their VRF treated declined less than those with none of their VRF treated. Those with some VRF treated tended to have an intermediate decline. CONCLUSIONS: In patients who have Alzheimer disease without CVD, treatment of vascular risk factors (VRF) is associated with a slower decline in Mini-Mental State Examination score. Randomized controlled trials are needed to confirm this association, but our data suggest that dementia should not prevent treatment of VRF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and may delay disease progression (Deschaintre et al., 2009), at least early in the disease course (Richard et al., 2010).”
From The Pathobiology of Vascular Dementia (2013) · cites this paper as Deschaintre et al., 2009
In the citing paper
“The new 2018 NIA-AA research framework dissociates AD symptoms or phenotypes from the pathologic process.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“Of individuals age 70 years or older, 20% to 40% without cognitive impairment have biomarker or autopsy evidence of AD pathology 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
In the citing paper
“It defines AD, for research purposes, purely in terms of a biopathologic construct with the AD biomarkers of amyloid, tau, and neurodegeneration (ATN) criteria, which aids in defining the disease stages. 2”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [2]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
The Pathobiology of Vascular Dementia
Iadecola, C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.008 · Cited by 1,857
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
“onset of symptoms.(2) The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues(18) conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations”
InfluentialThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557
“In support of this approach, treatment of vascular risk factors in AD patients slows down the cognitive decline [22].”
El Husseini, N., Katzan, I. L., Rost, N. S., Blake, M. L., Byun, E., Pendlebury, S. T., Aparicio, H. J., Marquine, M. J., Gottesman, R. F., Smith, E. E., et al. (2023) · Stroke · doi:10.1161/str.0000000000000430 · Cited by 539
Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease
Li, J., Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., & Zhou, H. D. (2011) · Neurology · doi:10.1212/wnl.0b013e318217e7a4 · Cited by 367
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
The Pericyte: A Forgotten Cell Type with Important Implications for Alzheimer's Disease?
Winkler, E. A., Sagare, A. P., & Zlokovic, B. V. (2014) · Brain Pathology · doi:10.1111/bpa.12152 · Cited by 278
“Conversely, control of vascular risk factors reduces vascular lesions in AD and may delay disease progression (40, 93, 135).”
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Mossello, E., Pieraccioli, M., Nesti, N., Bulgaresi, M., Lorenzi, C., Caleri, V., Tonon, E., Cavallini, M. C., Baroncini, C., Di Bari, M., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8164 · Cited by 247
Krol, S., Macrez, R., Docagne, F., Defer, G., Laurent, S., Rahman, M., Hajipour, M. J., Kehoe, P. G., & Mahmoudi, M. (2013) · Chemical Reviews · doi:10.1021/cr200472g · Cited by 216
An analysis of communication in conversation in patients with dementia
Rousseaux, M., Sève, A., Vallet, M., Pasquier, F., & Mackowiak-Cordoliani, M. A. (2010) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2010.09.026 · Cited by 178
Self-citationType 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach
Cholerton, B., Baker, L. D., Montine, T. J., & Craft, S. (2016) · Diabetes Spectrum · doi:10.2337/ds16-0041 · Cited by 170
“In patients already diagnosed with Alzheimer’s disease dementia and mild cognitive impairment, both cognitive and affective dysfunction were increased among those with insulin resistance (52,53), and treating vascular risk factors helped to slow cognitive decline (54).”
BackgroundThe Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease
Stakos, D. A., Stamatelopoulos, K., Bampatsias, D., Sachse, M., Zormpas, E., Vlachogiannis, N. I., Tual-Chalot, S., & Stellos, K. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.033 · Cited by 188
“Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.”
BackgroundInfluentialUpdate on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 163
“A prospective observational study shows that treatment of vascular risk factors in individuals with AD is associated with a slower cognitive decline [36].”
BackgroundO’Brien, J. T., & Burns, A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 164
Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer’s disease
Gupta, A., & Iadecola, C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00115 · Cited by 157
“Preliminary work to date has been promising, with studies suggesting that control of vascular risk factors may reduce MRI defined white matter lesions in AD and, at least early in the disease course, may delay AD progression (Rosenberg et al., 2008; Deschaintre et al., 2009; Richard et al., 2010; Valenti et al., 2014).”
BackgroundKorczyn, A. D., Vakhapova, V., & Grinberg, L. T. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.03.027 · Cited by 200
“[120] Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.”
BackgroundFaraco, G., Park, L., Zhou, P., Luo, W., Paul, S. M., Anrather, J., & Iadecola, C. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.79 · Cited by 158
“or slow down the progression of this devastating disease.(13,14) Hypertension is one of the vascular risk factors implicated in AD.”
BackgroundIntracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia
Roher, A. E., Tyas, S. L., Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Emmerling, M. R., Garami, Z., Belohlavek, M., Sabbagh, M. N., Sue, L. I., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.228 · Cited by 144
“It has been recently found that timely treatment of vascular risk factors slows the decline in the progression of AD [60].”
BackgroundPark, L., Wang, G., Moore, J., Girouard, H., Zhou, P., Anrather, J., & Iadecola, C. (2014) · Nature Communications · doi:10.1038/ncomms6318 · Cited by 139
Alzheimer's Disease is Incurable but Preventable
de la Torre, J. C. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091579 · Cited by 123
Pharmacological Treatment of Alzheimer Disease
Massoud, F., & Léger, G. C. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601003 · Cited by 120
Khan, A., Kalaria, R. N., Corbett, A., & Ballard, C. (2016) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988716654987 · Cited by 125
“There is also supporting evidence from a cohort study in people with AD indicating that better management of vascular risk factors such as hypertension, cholesterol, and diabetes significantly reduces the rate of cognitive decline.(238) It therefore seems likely that tight control of vascular risk factors is a key par…”
ResultChronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?
Humpel, C. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.032 · Cited by 124
Living alone and risk of dementia: A systematic review and meta-analysis
Desai, R., John, A., Stott, J. C. H., & Charlesworth, G. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101122 · Cited by 134
Ihle-Hansen, H., Thommessen, B., Bruun Wyller, T., Engedal, K., Øksengård, A. R., Stenset, V., Løken, K., Aaberg, M., & Fure, B. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335361 · Cited by 123
Fard, M. T., & Stough, C. K. K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00056 · Cited by 132
Stellos, K., Panagiota, V., Kögel, A., Leyhe, T., Gawaz, M., & Laske, C. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.140 · Cited by 118
“Moreover, treatment of vascular risk factors has been associated with reduced risk of developing AD (Forette et al, 2002) and with a slower cognitive decline in AD patients (Deschaintre et al, 2009).”
BackgroundPotential Predictors of Hippocampal Atrophy in Alzheimerʼs Disease
Dhikav, V., & Anand, K. S. (2010) · Drugs & Aging · doi:10.2165/11586390-000000000-00000 · Cited by 121
Qiu, C., Xu, W., & Fratiglioni, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091663 · Cited by 107
“vascular factors that are treated, the smaller the decline in global cognitive function [51].”
A European Academy of Neurology guideline on medical management issues in dementia
Frederiksen, K. S., Cooper, C., Frisoni, G. B., Frölich, L., Georges, J., Kramberger, M. G., Nilsson, C., Passmore, P., Ritter, L. M., Religa, D., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14412 · Cited by 118
“Summary of evidence One single-center retrospective cohort study was identified which reported on dementia patients with all three vascular risk factors [41] (Figure S2 and Tables S3 and S7).”
BackgroundHoffmann, M. (2013) · ISRN Neurology · doi:10.1155/2013/892459 · Cited by 90
“nonmemory presentations as an atypical subtype [172].”
Prevalence of Early Dementia After First-Ever Stroke: A 24-Year Population-Based Study
Béjot, Y., Aboa-Eboulé, C., Durier, J., Rouaud, O., Jacquin, A., Ponavoy, E., Richard, D., Moreau, T., & Giroud, M. (2011) · Stroke · doi:10.1161/strokeaha.110.595553 · Cited by 93
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease
Manukhina, E. B., Downey, H. F., Shi, X., & Mallet, R. T. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216649060 · Cited by 95
Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly
Samaras, K., Makkar, S. R., Crawford, J. D., Kochan, N. A., Slavin, M. J., Wen, W., Trollor, J. N., Brodaty, H., & Sachdev, P. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.041 · Cited by 87
Functions of amyloid precursor protein in metabolic diseases
Guo, Y., Wang, Q., Chen, S., & Xu, C. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154454 · Cited by 95
Wharton, W., Goldstein, F. C., Zhao, L., Steenland, K., Levey, A. I., & Hajjar, I. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13627 · Cited by 89
“with AD undergoing treatment of atherosclerosis and dyslipidemia than in untreated individuals.(23) In studies investigating conversion from MCI to AD, one study reported that treatment with any antihypertensive therapy was associated with slower disease conversion but only in participants with circulatory dysregulati…”
The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer’s disease
Pimentel‐Coelho, P. M., & Rivest, S. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08126.x · Cited by 85
“vascular risk factors prevents the progression of cognitive deficits in AD patients without cerebrovascular disease (Deschaintre et al., 2009), further suggesting that the prevention of cerebrovascular”
BackgroundVascular predictors of cognitive decline in patients with mild cognitive impairment
Viticchi, G., Falsetti, L., Vernieri, F., Altamura, C., Bartolini, M., Luzzi, S., Provinciali, L., & Silvestrini, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.027 · Cited by 96
“027 sion as well as the incidence of MCI and the rate of its progression to dementia, has stimulated the investigation of clinical and instrumental markers of increased risk for cerebrovascular disease in such conditions (Deschaintre et al., 2009; Li et al., 2011; Luchsinger et al., 2005).”
BackgroundAntihypertensive Treatments, Cognitive Decline, and Dementia
Duron, E., & Hanon, O. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091552 · Cited by 81
“However, when vascular risk factors were analyzed individually, antihypertensive treatments were not significantly associated with cognitive decline [36].”
BackgroundYamada, M., Ihara, M., Okamoto, Y., Maki, T., Washida, K., Kitamura, A., Hase, Y., Ito, H., Takao, K., Miyakawa, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016567 · Cited by 81
“risk factors, if present, should be thoroughly controlled in clinically probable AD patients [24].”
BackgroundRe-thinking the Etiological Framework of Neurodegeneration
Castillo, X., Castro-Obregón, S., Gutiérrez-Becker, B., Gutiérrez-Ospina, G., Karalis, N., Khalil, A. A., Lopez-Noguerola, J. S., Rodríguez, L. L., Martínez-Martínez, E., Perez-Cruz, C., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00728 · Cited by 79
Progressive Gray Matter Atrophy in Lacunar Patients with Vascular Mild Cognitive Impairment
Grau-Olivares, M., Arboix, A., Junqué, C., Arenaza-Urquijo, E. M., Rovira, M., & Bartrés-Faz, D. (2010) · Cerebrovascular Diseases · doi:10.1159/000316059 · Cited by 78
“WMH have been associated with frontal lobe executive dysfunction, which is the cognitive domain that worsened in our MCI-V patients. Finally, Deschaintre et al. [”
BackgroundPerrotta, M., Lembo, G., & Carnevale, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030347 · Cited by 85
“An epidemiological study reported that the treatment of vascular risk factors slows the cognitive decline in AD patients [18].”
BackgroundFrontal subcortical ischemia is crucial for post stroke cognitive impairment
Kandiah, N., Wiryasaputra, L., Narasimhalu, K., Karandikar, A. A., Marmin, M., Chua, E. V., & Sitoh, Y. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.07.013 · Cited by 81
New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Saito, S., & Ihara, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00290 · Cited by 73
“AD and CVD share common risk factors (Viswanathan et al., 2009; Kalaria et al., 2012), and treatment of vascular risk factors is associated with slower decline in cognitive impairments of AD patients (Deschaintre et al., 2009).”
BackgroundValverde-Salazar, V., Ruiz-Gabarre, D., & García‐Escudero, V. (2023) · Antioxidants · doi:10.3390/antiox12071460 · Cited by 85
Increased Myeloperoxidase Plasma Levels in Patients with Alzheimer's Disease
Tzikas, S., Schlak, D., Sopova, K., Gatsiou, A., Stakos, D., Stamatelopoulos, K., Stellos, K., & Laske, C. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131469 · Cited by 74
“AD is associated with all classical CVRFs that promote atherosclerosis [6].”
Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly
Umegaki, H., Hayashi, T., Nomura, H., Yanagawa, M., Nonogaki, Z., Nakshima, H., & Kuzuya, M. (2012) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2012.00922.x · Cited by 87
Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
van Norden, A. G. W., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olde-Rikkert, M. G. M., & de Leeuw, F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.003 · Cited by 88
A New Paradigm for the Treatment of Alzheimer's Disease: Targeting Vascular Activation
Grammas, P., Martinez, J. M., Sanchez, A. C., Yin, X., Riley, J., Gay, D., Desobry, K., Tripathy, D., Luo, J., Evola, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-132057 · Cited by 77
Blood–brain barrier impairment in dementia: Current and future in vivo assessments
van de Haar, H. J., Burgmans, S., Hofman, P. A. M., Verhey, F. R. J., Jansen, J. F. A., & Backes, W. H. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.022 · Cited by 76
Ihara, M., Okamoto, Y., & Takahashi, R. (2012) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2012.01.001 · Cited by 72
Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy
Hashizume, A., Katsuno, M., Banno, H., Suzuki, K., Suga, N., Mano, T., Atsuta, N., Oe, H., Watanabe, H., Tanaka, F., et al. (2012) · Brain · doi:10.1093/brain/aws170 · Cited by 68
Tokuchi, R., Hishikawa, N., Kurata, T., Sato, K., Kono, S., Yamashita, T., Deguchi, K., & Abe, K. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.09.012 · Cited by 68
“VRFs may be risk factors of incident AD, and treatment of VRFs reduces both dementia risk [10,27] and AD cognitive decline [28].”
BackgroundTreatment options and considerations for hypertensive patients to prevent dementia
Hernandorena, I., Duron, E., Vidal, J.-S., & Hanon, O. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1333599 · Cited by 61
“However, when vascular risk factors were analyzed individually, antihypertensive treatments were not significantly associated with cognitive decline [99].”
BackgroundPetek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01360-0 · Cited by 65
Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes
Caselli, R. J., Dueck, A. C., Locke, D. E. C., Sabbagh, M. N., Ahern, G. L., Rapcsak, S. Z., Baxter, L. C., Yaari, R., Woodruff, B. K., Hoffman-Snyder, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c3ae · Cited by 59
Cognitive and affective functions in Alzheimer's disease patients with metabolic syndrome
Hishikawa, N., Fukui, Y., Sato, K., Kono, S., Yamashita, T., Ohta, Y., Deguchi, K., & Abe, K. (2015) · European Journal of Neurology · doi:10.1111/ene.12845 · Cited by 63
“Treating people for VRFs effectively maintains cognitive decline in patients with AD [4].”
BackgroundIntegrating Health into Cognitive Aging: Toward a Preventive Cognitive Neuroscience of Aging
Spiro, A., & Brady, C. B. (2011) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbr018 · Cited by 61
Valenti, R., Pantoni, L., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0160-z · Cited by 51
“2009 [34] 280 consecutive AD NINCDS-ADRDA, DSM IV 208 treated (119 with some VRF treated and 89 with all VRF treated) versus 72 without treatment 27 MMSE”
BackgroundMethodInfluentialAspirin in Alzheimer’s Disease: Increased Risk of Intracerebral Hemorrhage: Cause for Concern?
Thoonsen, H., Richard, E., Bentham, P., Gray, R., van Geloven, N., De Haan, R. J., Van Gool, W. A., & Nederkoorn, P. J. (2010) · Stroke · doi:10.1161/strokeaha.109.576975 · Cited by 58
Zhang, M., Miao, L., Li, Y., & Hu, G. (2010) · Neuroscience Research · doi:10.1016/j.neures.2010.06.011 · Cited by 61
“Treatment of vascular risk factors can slow progression of AD (Deschaintre et al., 2009).”
Treating cognitive impairment with transcranial low level laser therapy
de la Torre, J. C. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.02.008 · Cited by 55
Hommet, C., Mondon, K., Constans, T., Beaufils, É., Desmidt, T., Camus, V., & Cottier, J. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335568 · Cited by 55
Impaired structural correlates of memory in Alzheimer's disease mice
Badhwar, A., Lerch, J. P., Hamel, E., & Sled, J. G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.08.017 · Cited by 45
“Since treatment of vascular risk factors and/or vascular co-morbidities has been shown to slow cognitive decline (Deschaintre et al., 2009; Li et al., 2011), pioglitazone may be of benefit to AD patients with concurrent cerebrovascular deficits.”
BackgroundLi, Z., Zhao, G., Qian, S., Yang, Z., Chen, X., Chen, J., Cai, C., Liang, X., & Guo, J. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.09.013 · Cited by 52
APOE ε4 and the Influence of Sex, Age, Vascular Risk Factors, and Ethnicity on Cognitive Decline
Makkar, S. R., Lipnicki, D. M., Crawford, J. D., Kochan, N. A., Castro-Costa, E., Lima-Costa, M. F., Diniz, B. S., Brayne, C., Stephan, B., Matthews, F., et al. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glaa116 · Cited by 43
“The fact that significant results were limited to younger women could be because men and women at this age range differed in the extent to which their vascular risk factors were treated (43) or in the combination of risk factors that contributed to their VRISK scores.”
BackgroundRapid cognitive decline in Alzheimer's disease: a literature review
Sona, A., Ellis, K. A., & Ames, D. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.859128 · Cited by 45
“Furthermore, in another study (Deschaintre et al., 2009) 301 consecutive AD patients without cardiovascular diseases from a memory clinic were divided into four groups on the basis of having untreated, treated (some), treated (all) or no CVRFs (hypertension, dyslipidaemia, diabetes, smoking,…”
BackgroundBaseline Cardiovascular Risk Predicts Subsequent Changes in Resting Brain Function
Beason‐Held, L. L., Thambisetty, M., Deib, G., Sojkova, J., Landman, B. A., Zonderman, A. B., Ferrucci, L., Kraut, M. A., & Resnick, S. M. (2012) · Stroke · doi:10.1161/strokeaha.111.638437 · Cited by 46
A turning point for Alzheimer's disease?
de la Torre, J. C. (2012) · BioFactors · doi:10.1002/biof.200 · Cited by 44
Neurovascular and Cognitive failure in Alzheimer’s Disease: Benefits of Cardiovascular Therapy
Hamel, É., Royea, J., Ongali, B., & Tong, X. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0285-4 · Cited by 47
Predictive value of olfactory impairment for cognitive decline among cognitively normal adults
Windon, M. J., Kim, S. J., Oh, E. S., & Lin, S. Y. (2019) · The Laryngoscope · doi:10.1002/lary.28166 · Cited by 46
“posed for examination in clinical trials include physical activity(42); a Mediterranean diet(43); and treatment of vascular risk factors including hypertension, dyslipidemia, diabetes, tobacco use, and atherosclerotic disease.(44) In addition, hearing loss has been highlighted as a potentiallymodifiable risk factor to…”
BackgroundA Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
“The earliest pathological signs of the disease seem to be more related to vascular factors than to Aβ accumulation, brain atrophy, and signs of cognitive decline [22,23].”
BackgroundWang, Y., Song, M., Yu, L., Wang, L., An, C., Xun, S., Zhao, X., Gao, Y., & Wang, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124566 · Cited by 40
“Besides, some studies also demonstrate that the treatment of VRFs can slow down the progression of cognitive impairment and dementia [9].”
BackgroundDodge, H. H., Zhu, J., Woltjer, R., Nelson, P. T., Bennett, D. A., Cairns, N. J., Fardo, D. W., Kaye, J. A., Lyons, D., Mattek, N., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.003 · Cited by 39
Soysal, P., Perera, G., Işık, A. T., Onder, G., Petrović, M., Cherubini, A., Maggi, S., Shetty, H., Molokhia, M., Smith, L., et al. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.02.019 · Cited by 42
Carbone, M. G., Pagni, G., Tagliarini, C., Imbimbo, B. P., & Pomara, N. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101420 · Cited by 42
Antidiabetic therapies and Alzheimer disease
Bendlin, B. B. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/bbendlin · Cited by 46
Vascular Risk Factors and Mild Cognitive Impairment in the Elderly Population in Southwest China
Zou, Y., Zhu, Q., Deng, Y., Duan, J., Pan, L., Tu, Q., Dai, R., Zhang, X., Chu, L., & Lü, Y. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513517042 · Cited by 43
“Meanwhile, some studies also demonstrate that the treatment of VRFs can delay the onset and progression of cognitive impairment and dementia.(10) However, till date there is still no final conclusion about the relations between VRFs and MCI, based on published data.”
ResultKakae, M., Nakajima, H., Tobori, S., Kawashita, A., Miyanohara, J., Morishima, M., Nagayasu, K., Nakagawa, T., Shigetomi, E., Koizumi, S., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0102 · Cited by 44
“Deschaintre et al. ( 39 ) reported that treatment of lifestyle-related diseases, which elicit CCH-associated SVD, such as diabetes, dyslipidemia, and hypertension, improves dementia.”
Lesser, G. T., Beeri, M. S., Schmeidler, J., Purohit, D. P., & Haroutunian, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563755 · Cited by 39
“In recent publications, several investigators noted beneficial effects of lipid-lowering agents (primarily “statins”) in development of AD [56, 57], in slowing the rate of cognitive decline in already established AD [58, 59], and in reducing Alzheimer neuropathology [60].”
BackgroundLow Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease
Chen, Y. S., Lille YOD study group BomboisStéphanieDr. BoutantinJustine CassagnaudPascalineDr. ChenYaohuaDr. DelbeuckXavier DelmaireChristineDr. DeramecourtVincentProf. GelePatrick Houssein-FoucherClaudeDr. JacquemontCharlotte LebertFlorenceDr. LebouvierThibaudDr. LopezRenaud MackowiakMarie-AnneDr. MaureilleAurélien PasquierFlorenceProf. PetytGrégoryDr. PolletMarianne Rollin-SillaireAdelineDr. SchraenSusannaDr. SemahFranckProf. VanhoutteMatthieu, Sillaire, A. R., Dallongeville, J., Skrobala, E., Wallon, D., Dubois, B., Hannequin, D., & Pasquier, F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170367 · Cited by 35
“Treatment of vascular risk factors (VRFs) in older patients has been associated with slower cognitive decline and later disease onset [7].”
BackgroundSelf-citationUrsin, M. H., Bergland, A., Fure, B., Thommessen, B., Hagberg, G., Øksengård, A. R., & Ihle‐Hansen, H. (2018) · Physiotherapy · doi:10.1016/j.physio.2018.07.007 · Cited by 41
Viticchi, G., Falsetti, L., Potente, E., Bartolini, M., & Silvestrini, M. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7226 · Cited by 37
“Several studies found that vascular risk factors have a significant impact on the onset (22-26) and the progression of cognitive impairment (27-29).”
Backgroundvan der Veere, P. J., Hoogland, J., Visser, L. N. C., van Harten, A. C., Rhodius‐Meester, H. F. M., Sikkes, S. A. M., Venkatraghavan, V., Barkhof, F., Teunissen, C. E., van de Giessen, E., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209605 · Cited by 35
de Oliveira, F. F., Chen, E., Smith, M. D. A. C., & Bertolucci, P. H. F. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000117 · Cited by 32
Lin, K., Chen, S., Lai, L., Huang, Y., Chen, J., Chen, T., Sun, Y., Wen, L., Yip, P., Chu, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020573 · Cited by 33
“Second, medications for treating cardiovascular or cerebrovascular diseases may affect the AD course [37].”
BackgroundReasons that prevent the inclusion of Alzheimer's disease patients in clinical trials
Rollin‐Sillaire, A., Breuilh, L., Salleron, J., Bombois, S., Cassagnaud, P., Deramecourt, V., Mackowiak, M., & Pasquier, F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04423.x · Cited by 28
Self-citationDoes statin use cause memory decline in the elderly?
Samaras, K., Brodaty, H., & Sachdev, P. S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.03.009 · Cited by 33
“[24] 301 72 (8) 2 31 Use at baseline No use at baseline Medical record examination Score change MMSE NR NR 12 63 A S E, base MMSE, ACEI, duration AD AFU NSD”
BackgroundMethodResultInfluentialDevelopment of a Multicomponent Intervention to Prevent Alzheimer's Disease
Saitô, S., Yamamoto, Y., & Ihara, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00490 · Cited by 31
“Conversely, intensive management of vascular risk factors was associated with reduced risk of dementia (25), as well as amelioration of cognitive decline in AD patients (27).”
Backgroundde Oliveira, F. F., Pivi, G. A. K., Chen, E., Smith, M. D. A. C., & Bertolucci, P. H. F. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.10.051 · Cited by 31
Vascular Risk Aggravates the Progression of Alzheimer's Disease in a Chinese Cohort
Li, J., Zhang, M., Xu, Z., Gao, C., Fang, C., Deng, J., Jia-chuan, Y., Wang, Y., & Zhou, H. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1383 · Cited by 30
“Given the fact that no strong disease-modifying prevention and treatment for AD are currently available, active intervention of vascular risk may delay the deterioration and development of AD, and thus would be a promising avenue to prevent the occurrence and hold the progression of AD [44].”
Kehoe, P. G., Davies, N. M., Martin, R. M., & Ben-Shlomo, Y. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121090 · Cited by 27
“pressure [41].”
Valenzuela, M., Esler, M., Ritchie, K. A., & Brodaty, H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.28 · Cited by 31
“In the clinic, an optimal dementia-treatment strategy may require management of the AD process, for example via cholinesterase inhibitors, as well as the CVD process, by aggressive reduction of cardiac risk factors and secondary stroke prevention.(20) In the context of public health, it elevates elimination of cardiac…”
MethodNieuwkerk, A. C. V., Pendlebury, S. T., Rothwell, P. M., & Study, F. T. O. V. (2021) · Stroke · doi:10.1161/strokeaha.120.031961 · Cited by 33
Rist, P. M., Capistrant, B. D., Wu, Q., Marden, J. R., & Glymour, M. M. (2014) · Neurology · doi:10.1212/wnl.0000000000000357 · Cited by 28
“Even traditional vascular risk factors, such as high blood pressure, dyslipidemia, diabetes mellitus, smoking, and atherosclerotic disease, may be untreated in those with cognitive impairment.(23) However, healthy risk factor profiles may help individuals with incipient dementia maintain functional independence, there…”
Background
Metadata
- Authors
- Deschaintre, Y., Richard, F., Leys, D., & Pasquier, F.
- Affiliations
- Inserm (FR)
- Venue
- Neurology
- Published
- 2009-09
- Volume
- 73
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986968958
- Cited by
- 232
- References
- 38
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 17 · 2018: 8 · 2017: 14 · 2016: 16 · 2015: 17 · 2014: 18 · 2013: 16 · 2012: 22
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Alzheimer's disease, vascular risk factors, cognitive decline, dyslipidemia, diabetes mellitus, smoking, atherosclerosis, cerebrovascular disease, Mini-Mental State Examination, dementia prevention, secondary prevention
- MeSH terms
- Aged, Alzheimer Disease, Hypolipidemic Agents, Cerebral Arteries, Intracranial Arteriosclerosis, Cerebrovascular Disorders, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Risk Factors, Risk Management, Time, Time Factors, Disease Progression, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.